30 results
6-K
EX-99.1
IMMP
Immutep Limited
2 May 24
Positive Initial Clinical Data Reported from Immutep’s Efti
6:16pm
therapeutic approaches including radiotherapy.
Katarzyna Kozak, M.D., Ph.D., and Paweł Sobczuk, M.D., Ph.D., medical oncologists at the Department
6-K
EX-99.1
IMMP
Immutep Limited
28 Jul 23
Current report (foreign)
6:31am
program. The trial’s Principal Investigators are Dr. Katarzyna Kozak, M.D., Ph.D., and Paweł Sobczuk, M.D., Ph.D., medical oncologists at the Department
6-K
EX-99.1
IMMP
Immutep Limited
26 May 23
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
6:10am
, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Abstract #: TPS1120
6-K
EX-99.1
IMMP
Immutep Limited
17 Apr 23
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
9:09pm
, Katarzyna Kozak, M.D., Ph.D., and Paweł Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma
6-K
EX-99.1
IMMP
Immutep Limited
31 Mar 23
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients
5:45pm
., Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, titled “Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble
6-K
EX-99.1
l8f2w5ozaer62
6 Sep 22
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
6:57pm
6-K
EX-99.1
itsqy2qsap9 n6dyj7py
18 May 22
Immutep Appoints Leading Oncologists to its Clinical Advisory Board
6:07am
6-K
EX-99.1
mjmwo5r
28 Jan 21
Immutep Announces Advancement of Phase Ii Trial for Eftilagimod Alpha In COVID-19 Patients to Randomised Portion of the Study
12:00am
6-K
EX-99.1
e806 zmmmh8zm43mktz
26 Oct 20
Immutep Announces the Start of an Investigator-Initiated
10:01am
6-K
EX-99.1
pqlz2
19 Dec 18
Current report (foreign)
7:18am
6-K
EX-99.1
5tj ztj7l845v9ba
20 Jan 15
Current report (foreign)
12:00am
6-K
EX-99.1
whov vsxz4ey64pyhpr
30 Dec 14
Prima Biomed Receives Nasdaq Notice of Bid Price Deficiency
12:00am